Macquarie shares jump on jobs shock and buyback extension — what to watch before the RBA meeting
22 January 2026
2 mins read

Macquarie shares jump on jobs shock and buyback extension — what to watch before the RBA meeting

Sydney, Jan 22, 2026, 17:38 AEDT — Market closed.

  • Macquarie Group (ASX:MQG) climbed 2.4%, closing at A$210.87.
  • The company pushed its on-market share buyback deadline to Nov. 6, 2026, having completed roughly A$1.013 billion so far.
  • Traders are focused on the inflation figures due Jan. 28 and the RBA’s rate decision on Feb. 3.

Macquarie Group shares ended a three-day losing streak on Thursday, climbing 2.4% to close at A$210.87. The uptick came as bank stocks gained ground following a better-than-expected jobs report. 1

The bounce is significant as MQG is back in play on the rate outlook. When investors bet on “higher rates for longer,” financial stocks typically get a boost, and Macquarie tends to follow suit.

It’s a balancing act: rising rates boost a lender’s earnings potential but also push up funding costs and pressure asset values. For Macquarie, a hybrid of bank, markets, and asset management, the impact isn’t straightforward.

Macquarie has extended its on-market share buyback program, now set to run through Nov. 6, 2026. The company plans to resume buying shares from Feb. 5, 2026, aiming to repurchase up to A$2 billion in ordinary shares. According to the latest filing, about A$1.013 billion had already been bought back as of Jan. 20. 2

The key macro update came mid-session. Australia’s unemployment rate dropped to 4.1% in December, with employment increasing by roughly 65,000, according to the Australian Bureau of Statistics. ABS head of labour statistics Sean Crick noted that a rise in jobs for 15–24 year olds played a big role in boosting employment. 3

Rates traders reacted quickly. Money markets now price in about a 57% chance of a 25 basis point hike — that’s 0.25 percentage points — at the Reserve Bank of Australia’s Feb. 3 meeting, a sharp jump from before the latest data, Reuters reported. The cash rate stands at 3.6%. UBS economists warned the labour market “needs to ease” to ease inflationary pressures, but “it’s going the wrong way.” Meanwhile, Oxford Economics Australia’s Harry Murphy Cruise pointed to 3.2% trimmed mean inflation—a core measure excluding volatile price swings—as the crucial figure in the December-quarter CPI report due Jan. 28. 4

Macquarie wasn’t the only gainer. National Australia Bank climbed roughly 2.5%, Commonwealth Bank added 1.6%, and Westpac rose about 1.1% near midday. MQG was up close to 2.4% at the same point. 5

Macquarie isn’t just a straightforward retail-bank play, and investors get that. Its profits fluctuate with commodity prices and financial markets, while its deal flow hinges entirely on confidence.

Thursday served as a reminder: when Australia shifts rates, MQG tends to move alongside — at least on the surface — even if the deeper factors aren’t so clear-cut.

The risk is clear. Jobs data often fluctuate and get revised, while next week’s inflation figures could upend the rate-hike play if they disappoint.

Traders are zeroing in on the Dec.-quarter CPI set for Jan. 28, the RBA’s decision on Feb. 3, and Macquarie’s planned buyback restart on Feb. 5 for the upcoming session and week.

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Woodside Energy share price jumps nearly 3% — here’s what moved WDS and what’s next
Previous Story

Woodside Energy share price jumps nearly 3% — here’s what moved WDS and what’s next

ANZ share price edges up as Suncorp job-cut row flares; CPI and RBA meeting loom
Next Story

ANZ share price edges up as Suncorp job-cut row flares; CPI and RBA meeting loom

Go toTop